+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anti Tumour Necrosis Factor"

From
From
From
From
From
From
From
From
From
From
North America Psoriasis Treatment Market Outlook, 2031 - Product Thumbnail Image

North America Psoriasis Treatment Market Outlook, 2031

  • Report
  • March 2026
  • 88 Pages
  • North America
From
Middle East & Africa Psoriasis Treatment Market Outlook, 2031 - Product Thumbnail Image

Middle East & Africa Psoriasis Treatment Market Outlook, 2031

  • Report
  • March 2026
  • 80 Pages
  • Middle East, Africa
From
Asia-Pacific Psoriasis Treatment Market Outlook, 2031 - Product Thumbnail Image

Asia-Pacific Psoriasis Treatment Market Outlook, 2031

  • Report
  • March 2026
  • 107 Pages
  • Asia Pacific
From
Europe Psoriasis Treatment Market Outlook, 2031 - Product Thumbnail Image

Europe Psoriasis Treatment Market Outlook, 2031

  • Report
  • March 2026
  • 104 Pages
  • Europe
From
US Rheumatoid Arthritis Therapeutics Market - Product Thumbnail Image

US Rheumatoid Arthritis Therapeutics Market

  • Report
  • October 2025
  • 89 Pages
  • United States
From
Loading Indicator

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications. The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more